[Reply on new drugs against type 2 diabetes: important to gain experience and knowledge].
Sjöholm
Ake
A
Karolinska institutet, Diabetescentrum, Södersjukhuset AB, Stockholm. ake.sjoholm@ki.se
Agardh
Carl-David
CD
Brismar
Kerstin
K
Efendic
Suad
S
Eliasson
Björn
B
Eriksson
Jan W
JW
Frid
Anders
A
Groop
Leif
L
Holmgren
Jan
J
Ridderstråle
Martin
M
Smith
Ulf
U
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D016903:Drug Monitoring; D000077270:Exenatide; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use; D010455:Peptides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014688:Venoms / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D007328:Insulin; D010455:Peptides; D011719:Pyrazines; D014230:Triazoles; D014688:Venoms; D000077270:Exenatide; D000068900:Sitagliptin Phosphate